Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Chronotropic Intolerance: An Overlooked Determinant of Symptoms and Activity Limitation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?

Davenport TE, Lehnen M, Stevens SR, VanNess JM, Stevens J, Snell CR.

Front Pediatr. 2019 Mar 22;7:82. doi: 10.3389/fped.2019.00082. eCollection 2019. Review.

2.

Checking our blind spots: current status of research evidence summaries in ME/CFS.

Davenport TE, Stevens SR, VanNess JM, Stevens J, Snell CR.

Br J Sports Med. 2019 Oct;53(19):1198. doi: 10.1136/bjsports-2018-099553. Epub 2018 Jul 17. No abstract available.

PMID:
30018122
3.

Discriminative validity of metabolic and workload measurements for identifying people with chronic fatigue syndrome.

Snell CR, Stevens SR, Davenport TE, Van Ness JM.

Phys Ther. 2013 Nov;93(11):1484-92. doi: 10.2522/ptj.20110368. Epub 2013 Jun 27.

PMID:
23813081
4.

Reliability and validity of Short Form 36 Version 2 to measure health perceptions in a sub-group of individuals with fatigue.

Davenport TE, Stevens SR, Baroni K, Van Ness JM, Snell CR.

Disabil Rehabil. 2011;33(25-26):2596-604. doi: 10.3109/09638288.2011.582925. Epub 2011 Jun 20.

PMID:
21682669
5.

Diagnostic accuracy of symptoms characterising chronic fatigue syndrome.

Davenport TE, Stevens SR, Baroni K, Van Ness M, Snell CR.

Disabil Rehabil. 2011;33(19-20):1768-75. doi: 10.3109/09638288.2010.546936. Epub 2011 Jan 6.

PMID:
21208154
6.

Closed loop folding units from structural alignments: experimental foldons revisited.

Chintapalli SV, Yew BK, Illingworth CJ, Upton GJ, Reeves PJ, Parkes KE, Snell CR, Reynolds CA.

J Comput Chem. 2010 Nov 30;31(15):2689-701. doi: 10.1002/jcc.21562.

PMID:
20839296
7.

Connectivity and binding-site recognition: applications relevant to drug design.

Illingworth CJ, Scott PD, Parkes KE, Snell CR, Campbell MP, Reynolds CA.

J Comput Chem. 2010 Nov 30;31(15):2677-88. doi: 10.1002/jcc.21561.

PMID:
20839295
8.

Conceptual model for physical therapist management of chronic fatigue syndrome/myalgic encephalomyelitis.

Davenport TE, Stevens SR, VanNess MJ, Snell CR, Little T.

Phys Ther. 2010 Apr;90(4):602-14. doi: 10.2522/ptj.20090047. Epub 2010 Feb 25.

PMID:
20185614
9.

Postexertional malaise in women with chronic fatigue syndrome.

VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR.

J Womens Health (Larchmt). 2010 Feb;19(2):239-44. doi: 10.1089/jwh.2009.1507.

PMID:
20095909
10.

Toward a consistent treatment of polarization in model QM/MM calculations.

Illingworth CJ, Parkes KE, Snell CR, Ferenczy GG, Reynolds CA.

J Phys Chem A. 2008 Nov 27;112(47):12151-6. doi: 10.1021/jp710168q.

PMID:
18986123
11.

Assessing the role of polarization in docking.

Illingworth CJ, Morris GM, Parkes KE, Snell CR, Reynolds CA.

J Phys Chem A. 2008 Nov 27;112(47):12157-63. doi: 10.1021/jp710169m.

PMID:
18986122
12.

Discovery of selective and nonpeptidic cathepsin S inhibitors.

Irie O, Ehara T, Iwasaki A, Yokokawa F, Sakaki J, Hirao H, Kanazawa T, Teno N, Horiuchi M, Umemura I, Gunji H, Masuya K, Hitomi Y, Iwasaki G, Nonomura K, Tanabe K, Fukaya H, Kosaka T, Snell CR, Hallett A.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3959-62. doi: 10.1016/j.bmcl.2008.06.009. Epub 2008 Jun 10.

PMID:
18572405
13.

Quantitative measurement of protease ligand conformation.

Illingworth CJ, Parkes KE, Snell CR, Reynolds CA.

J Comput Aided Mol Des. 2008 Feb;22(2):105-9. doi: 10.1007/s10822-008-9173-z. Epub 2008 Jan 19.

PMID:
18204905
14.

Criteria for confirming sequence periodicity identified by Fourier transform analysis: application to GCR2, a candidate plant GPCR?

Illingworth CJ, Parkes KE, Snell CR, Mullineaux PM, Reynolds CA.

Biophys Chem. 2008 Mar;133(1-3):28-35. Epub 2007 Nov 22.

PMID:
18086512
15.

Partial redirection of transgenic human growth hormone secretion from rat salivary glands.

Wang J, Cawley NX, Voutetakis A, Rodriguez YM, Goldsmith CM, Nieman LK, Hoque AT, Frank SJ, Snell CR, Loh YP, Baum BJ.

Hum Gene Ther. 2005 May;16(5):571-83.

PMID:
15916482
16.

Exercise capacity and immune function in male and female patients with chronic fatigue syndrome (CFS).

Snell CR, Vanness JM, Strayer DR, Stevens SR.

In Vivo. 2005 Mar-Apr;19(2):387-90.

17.
18.

Immunologic aspects of chronic fatigue syndrome. Report on a Research Symposium convened by The CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health.

Gerrity TR, Papanicolaou DA, Amsterdam JD, Bingham S, Grossman A, Hedrick T, Herberman RB, Krueger G, Levine S, Mohagheghpour N, Moore RC, Oleske J, Snell CR; CFIDS Association of America.

Neuroimmunomodulation. 2004;11(6):351-7. Review.

PMID:
15467349
19.

The prohormone processing enzyme PC3 is a lipid raft-associated transmembrane protein.

Arnaoutova I, Smith AM, Coates LC, Sharpe JC, Dhanvantari S, Snell CR, Birch NP, Loh YP.

Biochemistry. 2003 Sep 9;42(35):10445-55.

PMID:
12950171
20.

Disruption of a receptor-mediated mechanism for intracellular sorting of proinsulin in familial hyperproinsulinemia.

Dhanvantari S, Shen FS, Adams T, Snell CR, Zhang C, Mackin RB, Morris SJ, Loh YP.

Mol Endocrinol. 2003 Sep;17(9):1856-67. Epub 2003 Jun 26.

PMID:
12829804
21.

Subclassifying chronic fatigue syndrome through exercise testing.

Vanness JM, Snell CR, Strayer DR, Dempsey L 4th, Stevens SR.

Med Sci Sports Exerc. 2003 Jun;35(6):908-13.

PMID:
12783037
22.
23.

Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists.

Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Davies JW, Wrigglesworth R, Dunstan AR, Bloomfield GC, Drake GS, McIntyre P, Brown MC, Burgess GM, Lee W, Davis C, Yaqoob M, Phagoo SB, Phillips E, Perkins MN, Campbell EA, Davis AJ, Rang HP.

J Med Chem. 2002 May 23;45(11):2160-72.

PMID:
12014954
24.

Carboxypeptidase E, a prohormone sorting receptor, is anchored to secretory granules via a C-terminal transmembrane insertion.

Dhanvantari S, Arnaoutova I, Snell CR, Steinbach PJ, Hammond K, Caputo GA, London E, Loh YP.

Biochemistry. 2002 Jan 8;41(1):52-60.

PMID:
11772002
25.

Dimerization of G-protein-coupled receptors.

Dean MK, Higgs C, Smith RE, Bywater RP, Snell CR, Scott PD, Upton GJ, Howe TJ, Reynolds CA.

J Med Chem. 2001 Dec 20;44(26):4595-614.

PMID:
11741478
26.

Lipid-facing correlated mutations and dimerization in G-protein coupled receptors.

Gouldson PR, Dean MK, Snell CR, Bywater RP, Gkoutos G, Reynolds CA.

Protein Eng. 2001 Oct;14(10):759-67.

PMID:
11739894
27.

Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.

Dziadulewicz EK, Walpole CS, Snell CR, Wrigglesworth R, Hughes GA, Beattie D, Wood JN, Beech MM, Coote PR.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):705-9.

PMID:
11266174
28.

1-(2-Nitrophenyl)thiosemicarbazides: a novel class of potent, orally active non-peptide antagonist for the bradykinin B(2) receptor.

Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Ko SY, Wrigglesworth R, Hughes GA, Dunstan AR, Bloomfield GC, Drake GS, Brown MC, Lee W, Burgess GM, Davis C, Yaqoob M, Perkins MN, Campbell EA, Davis AJ, Rang HP.

J Med Chem. 2000 Mar 9;43(5):769-71. No abstract available.

PMID:
10715143
29.

Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia.

Burgess GM, Perkins MN, Rang HP, Campbell EA, Brown MC, McIntyre P, Urban L, Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Wrigglesworth R, Lee W, Davis C, Phagoo SB, Davis AJ, Phillips E, Drake GS, Hughes GA, Dunstan A, Bloomfield GC.

Br J Pharmacol. 2000 Jan;129(1):77-86.

30.
31.

Domain swapping in G-protein coupled receptor dimers.

Gouldson PR, Snell CR, Bywater RP, Higgs C, Reynolds CA.

Protein Eng. 1998 Dec;11(12):1181-93.

PMID:
9930667
32.
33.

Receptor-mediated targeting of hormones to secretory granules: role of carboxypeptidase E.

Loh YP, Snell CR, Cool DR.

Trends Endocrinol Metab. 1997 May-Jun;8(4):130-7.

PMID:
18406798
34.

The structure of synenkephalin (pro-enkephalin 1-73) is dictated by three disulfide bridges.

Lecchi P, Loh YP, Snell CR, Pannell LK.

Biochem Biophys Res Commun. 1997 Mar 27;232(3):800-5.

PMID:
9126357
35.

Carbohydrate analysis of the B2 bradykinin receptor from rat uterus.

Yaqoob M, Snell CR, Burgess GM.

J Neurochem. 1995 Sep;65(3):1290-6.

PMID:
7643106
36.

Identification of the sorting signal motif within pro-opiomelanocortin for the regulated secretory pathway.

Cool DR, Fenger M, Snell CR, Loh YP.

J Biol Chem. 1995 Apr 14;270(15):8723-9.

37.

Purification and characterisation of B2 bradykinin receptor from rat uterus.

Yaqoob M, Snell CR.

J Neurochem. 1994 Jan;62(1):17-26.

PMID:
8263517
38.

Characterization of bradykinin receptors solubilized from rat uterus and NG108-15 cells.

Snell PH, Phillips E, Burgess GM, Snell CR, Webb M.

Biochem Pharmacol. 1990 Jun 15;39(12):1921-8.

PMID:
2162171
40.

An iodinatable photoaffinity probe based on the structure of kallidin.

Webb M, Snell CR, Phillips E, Snell PH, de Vries JG.

Adv Exp Med Biol. 1989;247A:409-14. No abstract available.

PMID:
2557749
41.

Thyrotrophin releasing hormone degradation by rat synaptosomal peptidases: production of the metabolite His-Pro.

Coggins PJ, McDermott JR, Snell CR, Gibson AM.

Neuropeptides. 1987 Aug-Sep;10(2):147-56.

PMID:
2891073
42.

Autoradiographic visualization of binding sites for [3H]somatostatin in the rat brain.

Whitford CA, Candy JM, Snell CR, Hirst BH, Oakley AE, Johnson M, Thompson JE.

Eur J Pharmacol. 1987 Jun 26;138(3):327-33.

PMID:
2887442
43.

High affinity specific binding of the thyrotrophin releasing hormone metabolite histidylproline to rat brain membranes.

Coggins PJ, McDermott JR, Snell CR.

Neuropeptides. 1987 Jan;9(1):83-91. Erratum in: Neuropeptides 1987 May-Jun;9(4):379.

PMID:
3104816
44.

Regional distribution of high-affinity [3H]somatostatin binding sites in the human brain.

Whitford CA, Bloxham CA, Snell CR, Candy JM, Hirst BH.

Brain Res. 1986 Nov 19;398(1):141-7.

PMID:
3026563
45.

Histidyl-proline, a rapidly degraded metabolite of thyrotropin releasing hormone, has behavioural activity.

Coggins PJ, Sahgal A, McDermott JR, Snell CR, Keith AB, Edwardson JA.

Pharmacol Biochem Behav. 1986 May;24(5):1229-33.

PMID:
3088606
46.

Stereospecific binding sites for [3H]nicotinamide adenine dinucleotide in the rat brain.

Snell PH, Snell CR, Richards CD.

Eur J Pharmacol. 1985 Oct 8;116(1-2):121-7.

PMID:
4054211
47.

Human cerebellar cortex possesses high affinity binding sites for [3H]somatostatin.

Whitford CA, Candy JM, Bloxham CA, Oakley AE, Snell CR.

Eur J Pharmacol. 1985 Jul 11;113(1):129-32.

PMID:
2864261
48.

Rat brain membranes possess two high-affinity binding sites for [3H]somatostatin.

Weightman DR, Whitford CA, Snell CR, Hirst BH, Brundish DE, Kendall-Taylor PA.

Neurosci Lett. 1985 Apr 9;55(2):161-6.

PMID:
2860622
50.

Tolerance and withdrawal are associated with ligand dependent receptor regulation in vitro and in vivo.

Snell CR, Moses MA, Hughes DG.

Neuropeptides. 1984 Dec;5(1-3):23-6. No abstract available.

PMID:
6099504

Supplemental Content

Loading ...
Support Center